Latest Insider Transactions at Cyclerion Therapeutics, Inc. (CYCN)
This section provides a real-time view of insider transactions for Cyclerion Therapeutics, Inc. (CYCN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cyclerion Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cyclerion Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2024
|
Slate Path Capital LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
357,880
-100.0%
|
$357,880
$1.55 P/Share
|
|
Jan 01
2024
|
Regina Margaret Graul |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+33.27%
|
-
|
|
Jan 01
2024
|
Peter M Hecht |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+3.82%
|
-
|
|
Dec 01
2023
|
Peter M Hecht |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+3.97%
|
-
|
|
Nov 30
2023
|
Errol B Desouza |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+39.29%
|
-
|
|
Nov 30
2023
|
Peter M Hecht |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+5.44%
|
-
|
|
Nov 30
2023
|
Terrance Mcguire |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+47.38%
|
-
|
|
Nov 30
2023
|
Steven Hyman |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Aug 09
2023
|
Terrance Mcguire |
SELL
Open market or private sale
|
Indirect |
8
-100.0%
|
$24
$3.4 P/Share
|
|
May 19
2023
|
Peter M Hecht |
BUY
Grant, award, or other acquisition
|
Direct |
225,000
+40.73%
|
$1,800,000
$8.68 P/Share
|
|
Jun 03
2021
|
Peter M Hecht |
BUY
Open market or private purchase
|
Direct |
823,170
+28.67%
|
$2,469,510
$3.28 P/Share
|
|
Jun 03
2021
|
Terrance Mcguire |
BUY
Open market or private purchase
|
Indirect |
96,153
+11.75%
|
$288,459
$3.12 P/Share
|
|
Jun 03
2021
|
Slate Path Capital LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
961,538
+11.84%
|
$2,884,614
$3.12 P/Share
|
|
May 06
2021
|
Peter M Hecht |
BUY
Open market or private purchase
|
Direct |
302,000
+19.78%
|
$604,000
$2.43 P/Share
|
|
May 05
2021
|
Peter M Hecht |
BUY
Open market or private purchase
|
Direct |
398,001
+30.14%
|
$796,002
$2.53 P/Share
|
|
May 04
2021
|
Peter M Hecht |
BUY
Open market or private purchase
|
Direct |
300,000
+36.38%
|
$600,000
$2.29 P/Share
|
|
Feb 25
2021
|
Christopher I Wright Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,637
-5.81%
|
$7,911
$3.99 P/Share
|
|
Feb 25
2021
|
Anjeza Gjino Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,824
-5.46%
|
$7,296
$4.0 P/Share
|
|
Dec 28
2020
|
Mark G Currie President and CSO |
SELL
Open market or private sale
|
Direct |
20,107
-7.4%
|
$60,321
$3.01 P/Share
|
|
Nov 09
2020
|
Andreas Busch Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
125,000
+32.92%
|
$250,000
$2.53 P/Share
|
|
Nov 06
2020
|
William Huyett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,827
-5.36%
|
$7,654
$2.52 P/Share
|